MarketPulse
A

$ALNY

3 articles found
0 positive
0 negative
3 neutral
BenzingaBenzinga··Gav Blaxberg

Edgewise Therapeutics' $3.1B Bet on Two Blockbuster Drug Candidates

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.
BMYCELGrALNYEWTXFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development
BenzingaBenzinga··Vandana Singh

Tenaya Therapeutics Surges 31% on Alnylam Cardiovascular Research Deal

Tenaya Therapeutics surges 31% after partnering with Alnylam on cardiovascular genetic targets, securing $10M upfront and $1.13B in potential milestone payments.
TNYAALNYgene therapycardiovascular disease